Medpace Holdings, Inc. (MEDP) rises on deep earnings analysis
Medpace Holdings, Inc. (MEDP) rises after a Q3 earnings beat, but the deeper story is margin expansion, stronger bookings, and a growing backlog. This analysis goes beyond the headline to weigh guidance, segment mix, and what the latest quarter may signal for 2026.
Medpace Holdings (MEDP) reported a strong Q3 2026 beat, with GAAP EPS of $4.84 topping estimates and revenue of $716.0M edging past consensus. The quarter also showed healthier profitability, as EBITDA margin expanded to 24.0% and backlog rose to $3.167B, but investors are weighing that strength against a slightly softer full-year revenue outlook. For investors, the key takeaway is that Medpace is converting growth into better earnings quality, even if top-line momentum is not accelerating as fast as hoped.
Medpace Holdings, Inc. (MEDP) rises after earnings beat
Medpace Holdings, Inc. (MEDP) rises after Q3 2026 earnings beat estimates on both profit and revenue. GAAP EPS reached $4.84 versus the $4.44 consensus, while revenue came in at $716.0M against $714.47M expected. After-hours trading initially slipped 1.9%, but the latest regular-session close reached $662.48, up 6.43%.
The Medpace Holdings, Inc. earnings analysis centers on a clear split. Profitability, bookings, and margins strengthened, while the updated full-year revenue range sits slightly below the consensus cited after the quarter. That mix explains why the MEDP earnings call produced both optimism and caution.
Key Takeaways
Q3 GAAP EPS was $4.84, beating the $4.44 estimate, while revenue of $716.0M topped the $714.47M consensus.
Revenue increased 8.5% year over year, EBITDA rose 16.0% to $172.1M, and EBITDA margin expanded to 24.0% from 22.5%.
Net new business awards reached $873.4M, up 10.6%, while ending backlog rose 5.6% to $3.167B.
Oncology represented more than half of bookings in the latest management discussion, while new metabolic award notifications weakened from the prior year.
Updated 2026 revenue guidance is $2.835B to $2.855B, while EPS guidance is $17.97 to $18.32. The EPS range sits above the consensus cited after the quarter.
Analyst consensus remains Hold, with 4 Buy ratings, 15 Hold ratings, and zero Sell ratings. Mizuho and Barclays both raised price targets before the report.
MEDP Earnings Financial Performance: Growth, Margins, and Backlog
Medpace posted Q3 revenue of $716.0M, an 8.5% year-over-year increase. That result followed $707.3M of revenue in Q2, according to the prior quarterly financial discussion. The current quarter also extended a strong earnings pattern. The listed surprise history records EPS beats in five consecutive periods, moving from $3.86 versus $3.53 in October 2025 to $4.84 versus $4.44 in October 2026.
Profit growth outpaced sales growth. EBITDA rose 16.0% to $172.1M, and EBITDA margin expanded to 24.0% from 22.5%. That margin improvement gives the quarter more substance than a simple revenue beat. It shows that Medpace converted a larger share of its sales into operating earnings.
The booking data also supports the growth case. Net new business awards reached $873.4M, up 10.6% year over year. Ending backlog stood at $3.167B, up 5.6%. Bookings are not revenue, but the combination of higher awards and a larger backlog gives Medpace a firmer base for future sales.
The annual segment mix shows why the change in bookings matters. In 2025, oncology generated $747.585M of revenue, the largest segment, followed closely by metabolic at $744.957M. Other revenue was $408.548M, central nervous system revenue was $254.838M, cardiology was $239.371M, and antiviral and anti-infective revenue was $134.935M.
Management said oncology represented more than half of the latest bookings, while metabolic award notifications dropped. That shift matters because it reduces reliance on the metabolic programs that drove much of the recent top-customer growth. It also brings the pipeline closer to the historical oncology-heavy mix.
Medpace also announced a new $1.0B share repurchase authorization through Dec. 31, 2028. The new authorization replaces the prior program, which had $527.0M remaining. Buybacks add another support to per-share earnings, although the quarter's margin expansion and $4.84 EPS beat remain the more important operating signals.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
MEDP shares slipped 1.9% in after-hours trading as investors focused on the revenue outlook. The next regular-session move was stronger: the stock closed at $662.48, up 6.43%, on volume of 1,016,418 shares versus an average of 274,015. The reversal shows that investors gave more weight to the earnings beat, margin expansion, and buyback authorization than to the modest revenue-guidance gap.
The guidance mix remains the central valuation issue. Medpace now expects 2026 revenue of $2.835B to $2.855B, compared with the $2.852B consensus cited after the report. At the same time, EPS guidance of $17.97 to $18.32 sits above the consensus cited in the post-earnings commentary. In plain English, the company sees stronger earnings quality than top-line momentum.
Analyst positioning was constructive before the MEDP earnings report, but the overall consensus remained Hold. Mizuho raised its target from $665 to $700 and kept an Outperform rating on Oct. 7, 2026. Barclays lifted its target from $600 to $625 while keeping Equal-Weight on the same date. UBS resumed coverage at Neutral with a $673 target on Sept. 30.
UBS wrote that strong Q2 results had set a higher bar for bookings and earnings in the second half of 2026. That comment captures the investment setup: Medpace beat the quarter, but the stock had already attracted higher expectations. The published analyst target range runs from $370 to $700, with an average target of $595.92.
Management Commentary: Oncology, Cancellations, and 2026 Guidance
CEO August Troendle emphasized stronger demand and improved cancellation behavior in the operating backdrop. His comments also pointed to a strategic shift from metabolic work toward oncology. That change matters because top-five customer growth has been tied closely to large metabolic programs.
"The business environment was strong in Q2 26. Cancellations were well behaved, and supported a record quarter for net bookings." - August Troendle, CEO, Earnings Call
CFO Kevin Brady's earlier guidance provides a useful comparison with the latest update. He previously set 2026 revenue guidance at $2.805B to $2.885B and EPS guidance at $17.25 to $17.95. The newer Q3 update narrowed revenue to $2.835B to $2.855B and raised EPS to $17.97 to $18.32.
"Earnings per diluted share is now expected to be in the range of $17.25 to $17.95." - Kevin Brady, CFO, Earnings Call
The contrast between the old and new ranges is important. Revenue guidance became tighter, while the EPS range moved higher. That outcome fits the quarter's 24.0% EBITDA margin and points to cost control, mix, or both supporting earnings.
Analyst Q&A Highlights from the MEDP Earnings Call
The Q&A focused on concentration risk, backlog conversion, and cancellation volatility. Those exchanges exposed the limits of using bookings alone as a straight-line forecast for revenue.
"Are the two related in such that maybe a lot of the metabolic work you are doing is coming from a couple large clients?" - Charles Rhyee, TD Cowen
"The top 5 growth has been driven quite a bit by that metabolic work." - August Troendle, CEO, Earnings Call
Troendle confirmed the link between customer concentration and metabolic programs. He then added that oncology represented more than half of bookings in the latest quarter, while metabolic award notifications had declined. The answer defended the current growth rate, but it also conceded that some of the largest metabolic programs are reducing. That creates a more balanced pipeline, yet it removes some of the easiest fuel from the recent growth story.
"Do you feel going forward, like, cancellations should be at least in a better place versus what was seemingly an outlier in one quarter?" - Michael Cherny, Leerink Partners
"I cannot say that. But what I can say is that the business environment is good." - August Troendle, CEO, Earnings Call
That exchange was the most cautious part of the discussion. Management did not promise that cancellations would stay low, even after the latest quarter showed better behavior. Instead, Troendle pointed to a strong opportunity pipeline and higher gross bookings as the more reliable operating signal. For investors, that distinction matters: backlog growth is useful, but cancellations can still change the pace of conversion.
Bottom Line
MEDP delivered a strong quarter, with a clear EPS beat, higher margins, stronger bookings, and a larger buyback authorization. The main risk is not current profitability; it is whether oncology bookings can replace cooling metabolic demand while cancellations remain unpredictable. For investors, the latest results support the business case, but the Hold consensus and $662.48 share price leave less room for execution errors.
Yes. Medpace reported GAAP EPS of $4.84 versus the $4.44 consensus, and revenue of $716.0M versus $714.47M expected.
+Why did MEDP stock rise after the earnings report?
The stock rose because Medpace beat on both profit and revenue, expanded EBITDA margin to 24.0%, and raised 2026 EPS guidance. Investors also reacted positively to the $1.0B share repurchase authorization and stronger backlog.
+What was Medpace's 2026 guidance after Q3 earnings?
Medpace guided 2026 revenue to $2.835B-$2.855B and EPS to $17.97-$18.32. The EPS range is above the consensus cited after the report, while the revenue range is slightly below the consensus cited in the article.
+How strong were Medpace's bookings and backlog in Q3 2026?
Net new business awards reached $873.4M, up 10.6% year over year. Ending backlog increased 5.6% to $3.167B, giving the company a stronger base for future revenue.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on MEDP?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
